home / stock / lbph / lbph news


LBPH News and Press, Longboard Pharmaceuticals Inc.

Stock Information

Company Name: Longboard Pharmaceuticals Inc.
Stock Symbol: LBPH
Market: NASDAQ
Website: longboardpharma.com

Menu

LBPH LBPH Quote LBPH Short LBPH News LBPH Articles LBPH Message Board
Get LBPH Alerts

News, Short Squeeze, Breakout and More Instantly...

LBPH - (LBPH) Investment Report

2024-07-16 13:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

LBPH - Objective long/short (LBPH) Report

2024-07-06 15:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

LBPH - F, SIRI, INFN, LBPH, FIGS showing five-day upward surge

2024-07-02 10:45:05 ET Ford Motor Co. (F) F is trading UP for the last 5 days, and it at trading at $12.82 with volume of 15,047,573 and a one day change of $0.06 (0.47%). Ford Motor Co. has a 52-week low of 9.63 and a 52-week high of $15.42. The business's 50-day moving average pri...

LBPH - LBPH Price Target Alert: $90.00. Issued by Cantor Fitzgerald

2024-07-01 14:00:07 ET Josh Schimmer from Cantor Fitzgerald issued a price target of $90.00 for LBPH on 2024-07-01 12:46:00. The adjusted price target was set to $90.00. At the time of the announcement, LBPH was trading at $28.76. The overall price target consensus is at...

LBPH - Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical...

LBPH - Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3% Favorable safety and tolerability results observed ...

LBPH - Long Term Trading Analysis for (LBPH)

2024-05-26 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

LBPH - SBRA, GH and CRBU are among after hour movers

2024-05-20 16:47:47 ET Gainers: Maravai LifeSciences  ( MRVI ) +5% . Caribou Biosciences ( CRBU ) +4% . Greenidge Generation Holdings  ( GREE ) +4% . Cipher Mining  ( CIFR ) +4% . SIGA Technologies  ( SIGA ) +4%...

LBPH - Longboard Pharmaceuticals EPS of -$0.42 beats by $0.07

2024-05-03 14:53:23 ET More on Longboard Pharmaceuticals Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely Longboard stock up 8% as Citi initiates at buy, citing takeover potential Seeking Alpha’s Quant Rating on Longboard ...

LBPH - Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1 2024 Presented late-breaking data for bexicaserin from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeti...

Next 10